Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
Adolescent
Adult
Aged
Algorithms
Bacterial Proteins
/ analysis
Bacterial Toxins
/ analysis
Child
Child, Preschool
Clinical Laboratory Techniques
Clostridioides difficile
Clostridium Infections
/ diagnosis
Feces
/ chemistry
Female
Humans
Immunoenzyme Techniques
Infant
Logistic Models
Male
Middle Aged
Nucleic Acid Amplification Techniques
Young Adult
Clostridioides difficile infection
CDI
diagnostic testing
outcomes
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
30 10 2019
30 10 2019
Historique:
received:
26
09
2018
accepted:
04
01
2019
pubmed:
8
1
2019
medline:
26
9
2020
entrez:
8
1
2019
Statut:
ppublish
Résumé
Few data suggest that Clostridioides difficile infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcomes than those detected by nucleic acid amplification tests (NAATs) only. We compared toxin- positive and NAAT-positive-only CDI across geographically diverse sites. A case was defined as a positive C. difficile test in a person ≥1 year old with no positive tests in the prior 8 weeks. Cases were detected during 2014-2015 by a testing algorithm (specimens initially tested by glutamate dehydrogenase and toxin EIA; if discordant results, specimens were reflexed to NAAT) and classified as toxin positive or NAAT positive only. Medical charts were reviewed. Multivariable logistic regression models were used to compare CDI-related complications, recurrence, and 30-day mortality between the 2 groups. Of 4878 cases, 2160 (44.3%) were toxin positive and 2718 (55.7%) were NAAT positive only. More toxin-positive than NAAT-positive-only cases were aged ≥65 years (48.2% vs 38.0%; P < .0001), had ≥3 unformed stools for ≥1 day (43.9% vs 36.6%; P < .0001), and had white blood cell counts ≥15 000 cells/µL (31.4% vs 21.4%; P < .0001). In multivariable analysis, toxin positivity was associated with recurrence (adjusted odds ratio [aOR], 1.89; 95% confidence interval [CI], 1.61-2.23), but not with CDI-related complications (aOR, 0.91; 95% CI, .67-1.23) or 30-day mortality (aOR, 0.95; 95% CI, .73-1.24). Toxin-positive CDI is more severe, but there were no differences in adjusted CDI-related complication and mortality rates between toxin-positive and NAAT-positive-only CDI that were detected by an algorithm that utilized an initial glutamate dehydrogenase screening test.
Sections du résumé
BACKGROUND
Few data suggest that Clostridioides difficile infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcomes than those detected by nucleic acid amplification tests (NAATs) only. We compared toxin- positive and NAAT-positive-only CDI across geographically diverse sites.
METHODS
A case was defined as a positive C. difficile test in a person ≥1 year old with no positive tests in the prior 8 weeks. Cases were detected during 2014-2015 by a testing algorithm (specimens initially tested by glutamate dehydrogenase and toxin EIA; if discordant results, specimens were reflexed to NAAT) and classified as toxin positive or NAAT positive only. Medical charts were reviewed. Multivariable logistic regression models were used to compare CDI-related complications, recurrence, and 30-day mortality between the 2 groups.
RESULTS
Of 4878 cases, 2160 (44.3%) were toxin positive and 2718 (55.7%) were NAAT positive only. More toxin-positive than NAAT-positive-only cases were aged ≥65 years (48.2% vs 38.0%; P < .0001), had ≥3 unformed stools for ≥1 day (43.9% vs 36.6%; P < .0001), and had white blood cell counts ≥15 000 cells/µL (31.4% vs 21.4%; P < .0001). In multivariable analysis, toxin positivity was associated with recurrence (adjusted odds ratio [aOR], 1.89; 95% confidence interval [CI], 1.61-2.23), but not with CDI-related complications (aOR, 0.91; 95% CI, .67-1.23) or 30-day mortality (aOR, 0.95; 95% CI, .73-1.24).
CONCLUSIONS
Toxin-positive CDI is more severe, but there were no differences in adjusted CDI-related complication and mortality rates between toxin-positive and NAAT-positive-only CDI that were detected by an algorithm that utilized an initial glutamate dehydrogenase screening test.
Identifiants
pubmed: 30615074
pii: 5274659
doi: 10.1093/cid/ciz009
pmc: PMC6612464
mid: NIHMS1025174
doi:
Substances chimiques
Bacterial Proteins
0
Bacterial Toxins
0
Types de publication
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1667-1674Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
Clin Microbiol Infect. 2018 Apr;24(4):414-421
pubmed: 28811244
Clin Infect Dis. 2011 Aug 1;53(3):287-90
pubmed: 21765078
Clin Infect Dis. 2008 Nov 1;47(9):1162-70
pubmed: 18808358
N Engl J Med. 2014 Mar 27;370(13):1198-208
pubmed: 24670166
Clin Infect Dis. 2019 Jan 1;68(1):78-86
pubmed: 29788296
J Clin Microbiol. 2007 Jun;45(6):1963-4
pubmed: 17428945
Clin Infect Dis. 2019 Feb 1;68(4):711
pubmed: 30137260
J Clin Microbiol. 2010 Oct;48(10):3719-24
pubmed: 20702676
CMAJ. 2004 Aug 31;171(5):466-72
pubmed: 15337727
JAMA Intern Med. 2015 Nov;175(11):1792-801
pubmed: 26348734
Clin Infect Dis. 2013 Jan;56(1):67-73
pubmed: 23011147
N Engl J Med. 2005 Dec 8;353(23):2442-9
pubmed: 16322602
Clin Microbiol Infect. 2014 Oct;20(10):1067-73
pubmed: 24813402
Clin Infect Dis. 2018 Mar 19;66(7):1004-1012
pubmed: 29136126
Clin Microbiol Rev. 2013 Jul;26(3):604-30
pubmed: 23824374
J Clin Microbiol. 2012 Apr;50(4):1303-7
pubmed: 22238444
Lancet. 2005 Sep 24-30;366(9491):1079-84
pubmed: 16182895
Clin Infect Dis. 2014 May;58(10):1394-400
pubmed: 24604900
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
J Hosp Infect. 2013 Aug;84(4):311-5
pubmed: 23831282
Lancet Infect Dis. 2013 Nov;13(11):936-45
pubmed: 24007915
Ann Surg. 2002 Mar;235(3):363-72
pubmed: 11882758
Gut. 2004 May;53(5):673-7
pubmed: 15082585
Nat Rev Immunol. 2013 Nov;13(11):790-801
pubmed: 24096337
N Engl J Med. 2005 Dec 8;353(23):2433-41
pubmed: 16322603
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1137-1142
pubmed: 29627950
J Antimicrob Chemother. 2017 Jan;72(1):128-136
pubmed: 27707993
Infect Control Hosp Epidemiol. 2018 Jul;39(7):863-866
pubmed: 29690940
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
J Gastroenterol Hepatol. 2017 Feb;32(2):415-419
pubmed: 27505006